Please select the option that best describes you:
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
Are there specific scenarios where it could be considered?
Answer from: at Academic Institution
I would not use Toci prophylactically. I see more problems with ICANS/confusion in MM bispecifics, and this responds to steroids, not Toci, or resolves on its own.
Sign in or Register to read more